The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Ramelteon | Takeda Global Research Development Centre (Europe) Ltd. | Sleep Initiation and Maintenance Disorders | 🇪🇺 EU | Order → |
| Ramvocid oritavancin | Targanta Netherlands B.V. | Gram-Positive Bacterial Infections; Skin Diseases, Bacterial; Soft Tissue Infections | 🇪🇺 EU | Order → |
| Rasival | Novartis Europharm Ltd | 🇪🇺 EU | Order → | |
| Rasonque Daraxonrasib Orphan | Revolution Medicines Netherlands B.V. | Pancreatic Neoplasms | 🇪🇺 EU 2026-10-15 | Order → |
| Ratioepo epoetin theta | Ratiopharm GmbH | Anemia; Kidney Failure; Cancer | 🇪🇺 EU | Order → |
| Raxone idebenone Orphan | Santhera Pharmaceuticals (Deutschland) GmbH | Eye Diseases | 🇪🇺 EU | Order → |
| Raylumis tanezumab | Pfizer Europe MA EEIG | Osteoarthritis; Pain | 🇪🇺 EU 2021-09-16 | Order → |
| Rayoqta abicipar pegol | Allergan Pharmaceuticals International Limited | Macular Degeneration | 🇪🇺 EU | Order → |
| Reasanz serelaxin | Novartis Europharm Ltd | Heart Failure | 🇪🇺 EU 2014-05-22 | Order → |
| Recothrom thrombin alfa | Bayer Schering Pharma AG | 🇪🇺 EU | Order → | |
| Repaglinide Sun repaglinide Generic | Sun Pharmaceutical Industries B.V. | Diabetes Mellitus, Type 2 | 🇪🇺 EU | Order → |
| Restaysis ciclosporin | Allergan Pharmaceuticals International Limited | Dry Eye Syndromes | 🇪🇺 EU | Order → |
| Retaane anecortave acetate | Alcon Laboratories (U.K.) Limited. | Wet Macular Degeneration | 🇪🇺 EU | Order → |
| Retisert fluocinolone acetonide Orphan | Bausch Lomb Ireland | 🇪🇺 EU | Order → | |
| Rhucin recombinant human C1 inhibitor | Pharming Group N.V. | Angioedema | 🇪🇺 EU 2007-12-13 | Order → |
| Rilonacept FGK Representative Service GmbH rilonacept Orphan | Rilonacept FGK Representative Service GmbH | Pericarditis | 🇪🇺 EU | Order → |
| Riociguat Accord riociguat Generic | Accord Healthcare S.L.U. | Hypertension, Pulmonary; Pulmonary Arterial Hypertension | 🇪🇺 EU 2026-07-23 | Order → |
| Riquent abetimus | La Jolla Limited | Lupus Nephritis | 🇪🇺 EU | Order → |
| Rituximab Mabion rituximab | Mabion Spolka Akcyjna | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; Arthritis, Rheumatoid; Microscopic Polyangiitis | 🇪🇺 EU | Order → |
| Roctavian valoctocogene roxaparvovec Orphan | BioMarin International Limited | Hemophilia A | 🇪🇺 EU | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.